Clinical trials: Essential (Primary) Hypertension
Hypertension, Primary Hypercholesterolaemia
To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel group, Phase 3 trial to Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients with Essential Hypertension and Primary…
- Trial name
- HODO-2224 (NCT06646354)
- Testing
- Ezetimibe/Rosuvastatin/Candesartan/Amlodipine, Candesartan/Amlodipine, Candesartan/Rosuvastatin/Ezetimibe
- Where
- South Korea
- Volunteers
- 125 people
- Sponsor
- Hyundai Pharm
Primary Hypercholesterolemia, Hypertension
To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia
This study is a multicenter, Randomized, double-blind, acitve-controlled, Phase 3 Clinical Trial in 8 weeks for screening, twice Investigational product administer, Follow up visit.
- Trial name
- NCT04659070
- Testing
- Experimental : Ezetimibe / Rosuvastatin + Telmisartan, Active comparator1 : Ezetimibe / Rosuvastatin, Active comparator2 : Telmisartan
- Where
- South Korea
- Volunteers
- 156 people
- Sponsor
- Hanlim Pharm. Co., Ltd.
Hypertension
CKD-828 Telmisartan Non-Responder Trial
The aim of the present study is to evaluate the efficacy and safety of two dose combination of Telmisartan/S-Amlodipine (40/2.5mg and 40/5mg) compared with telmisartan monotherapy (80mg) in hypertensive patients inadequately…
- Trial name
- NCT01426100
- Testing
- CKD-828 40/2.5mg, CKD-828 40/5mg, Telmisartan 80mg
- Where
- 18 sites in South Korea
- Volunteers
- 183 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Primary Hypertension
A National Multicentre Study to Assess the Efficacy of the Fixed Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled by Monotherapy
This study is to assess the efficacy of the fixed combination of Valsartan and Amlodipine in hypertensive patients uncontrolled by monotherapy.
- Trial name
- NCT01241487
- Testing
- valsartan/amlodipine
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Novartis
Hypertension, Renal
RENABLATE Feasibility Study CS156 (EC12-02) Study of Catheter Based Renal Denervation to Treat Resistant Hypertension
The RENABLATE feasibility study is a prospective, multi-center, non-randomized feasibility study to evaluate the safety and effectiveness of the investigational multi-electrode ablation catheter and integrated ablation system to…
- Trial name
- NCT01756300
- Testing
- Celsius® ThermoCool® RD
- Volunteers
- 35 people
- Sponsor
- Biosense Webster, Inc.
Primary Hypertension
Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets
This study aims to evaluate the bioequivalence and safety of single oral administration of Sacubitril/Valsartan/Amlodipine Tablets (240mg/5mg) versus Sacubitril/Valsartan Calcium Tablets (240mg) combined with Amlodipine Besylate…
- Trial name
- NCT07486453
- Testing
- Sequence A T-R-T-R, Sequence B R-T-R-T
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Hypertension
CKD-828(80/2.5mg) Pharmacokinetic Study_2nd
The purpose of this study is to evaluate the pharmacokinetic characteristics of CKD-828(Fixed Dose Combination Tablet; Telmisartan and S-Amlodipine) in healthy volunteer.
- Trial name
- NCT01352689
- Testing
- CKD-828(FDC), Combination Therapy
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Primary Hypertension
A Study to Compare to PK Characteristics and Safety Profiles Between AD-227 and Co-administration of AD-227A and AD-227B
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-227 in healthy subjects.
- Trial name
- NCT06884085
- Testing
- Co-administration of AD-227A and AD-227B, Administration of AD-227
- Where
- South Korea
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Hypertension, Congestive Heart Failure
To Evaluate the Efficacy and Safety on Blood Pressure In Patients With Hypertension Diagnosed Congestive Heart Failure
To compare and evaluate the efficacy and safety of Candemore tab. versus Atacand tab. on blood pressure in patients with hypertension diagnosed congestive heart failure
- Trial name
- CANTABILE (NCT01682564)
- Testing
- Candemore tablet, Atacand tablet
- Where
- 14 sites in South Korea
- Volunteers
- 169 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension, Essential, Primary Hypercholesterolemia
Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022
The purpose of this study is to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022
- Trial name
- NCT06448962
- Testing
- AD-2021, AD-2022
- Where
- South Korea
- Volunteers
- 109 people
- Sponsor
- Addpharma Inc.
Essential (Primary) Hypertension, Hypertensive Heart Disease With (Congestive) Heart Failure
Positive Care Effect of the Digital Health Assistant ADELE Blood Pressure for Hypertension Patients
High blood pressure (hypertension) can cause damage to vital organs such as the heart, kidneys, eyes, brain and blood vessels. The risk of developing high blood pressure increases with age.
- Conditions
- Essential (Primary) Hypertension, Hypertensive Heart Disease With (Congestive) Heart Failure, Hypertensive Heart Disease Without (Congestive) Heart Failure, Other Secondary Hypertension
- Trial name
- A0007 (NCT06663280)
- Testing
- Digital health assistant ADELE
- Where
- 2 sites in Germany
- Volunteers
- 108 people
- Sponsor
- Alma Phil Gmbh
Primary Hypertension
Effects of Telmisartan/Hydrochlorothiazide Treatment in Hypertensive Patients Under Real-life Setting
One of the most common adverse effects resulting from the therapy with thiazides, thiazide-like diuretics and loop diuretics is increased potassium secretion.
- Trial name
- POTASSIUM (NCT01392534)
- Testing
- Telmisartan/hydrochlorothiazide (Pritor Plus, BAY98-7103)
- Where
- Poland
- Volunteers
- 1,586 people
- Sponsor
- Bayer
Essential Hypertension, Primary Hypercholesterolemia
A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia
The objective of this clinical study is to evaluate the efficacy and safety by comparing BR1017A+BR1017B treatment group to BR1017A treatment group and BR1017B treatment group respectively at Week 8 in essential hypertension…
- Trial name
- NCT05930028
- Testing
- Fimasartan, Ezetimibe/Atorvastatin
- Where
- South Korea
- Volunteers
- 148 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
This double-blind 8 week study will evaluate dose response, efficacy (blood pressure lowering effect) and safety of aliskiren in children 6 - 17 years old with hypertension at low, mid and high weight-based doses.
- Trial name
- NCT01150357
- Testing
- Aliskiren (6.25/12.5/25 mg), Aliskiren (37.5/75/150 mg), Aliskiren (150/300/600 mg)
- Where
- 48 sites in United States, Belgium and 7 more
- Volunteers
- 267 people
- Sponsor
- Novartis Pharmaceuticals
Primary Hypertension
A Study to Compare the Efficacy, Safety and Tolerability of Selomax With Its Individual Components
This is a randomised, open-label; parallel group, multicentric study comparing the efficacy and safety of fixed-dose-combinations of Metoprolol XL plus Amlodipine with individual components of the combination.
- Trial name
- MARS (NCT00819104)
- Testing
- Metoprolol XL 50mg + Amlodipine 5mg, Metoprolol XL 25 mg + Amlodipine 2.5mg, Metoprolol XL 50mg
- Where
- 11 sites in India
- Volunteers
- 402 people
- Sponsor
- AstraZeneca
Primary Hypertension
China Stroke Primary Prevention Trial
The purpose of this trial is to confirm that enalapril maleate and folic acid tablets is more effective in preventing stroke among the patients with primary hypertension when compared to enalapril maleate.
- Trial name
- CSPPT (NCT00794885)
- Testing
- Enalapril/folic acid, Enalapril maleate
- Where
- 2 sites in China
- Volunteers
- 20,702 people
- Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd
Essential Arterial Hypertension
Fixed-dose Combination of an Angiotensin Receptor Blocker and Thiazide Diuretic for Essential Hypertension
This is a phase III, non-inferiority, randomized, double-blind, double-dummy, active-controlled, multicenter study to compare the efficacy and safety of N0877 versus double combination with already established efficacy on…
- Trial name
- ATHESA (NCT06608472)
- Testing
- N0877, Benicar HCT ® Tablets 40 mg/25 mg
- Sponsor
- Eurofarma Laboratorios S.A.
Essential Hypertension, Primary Hypercholesterolemia
To Evaluate the Renal Protective Effects and Safety of 'Fimasartan and Atorvastatin' or 'Fimasartan, Atorvastatin and Ezetimibe'.
This prospective study aims to observe changes in renal function and related parameters in patients with essential hypertension and primary hypercholesterolemia receiving either the combination of fimasartan and atorvastatin or…
- Trial name
- NCT07685054
- Volunteers
- 12,700 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension, Primary Hypercholesterolemia
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1017-1" and Co-administration of "BR1017-1A" and "BR1017-1B"
The objective of this clinical study is to evaluate the pharmacokinetics and the safety after administration of "BR1017-1" and co-administration of "BR1017-1A" and "BR1017-1B" in healthy volunteers
- Trial name
- NCT06184269
- Testing
- BR1017-1, BR1017-1A, BR1017-1B
- Where
- South Korea
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension, Primary Hypercholesterolemia
A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C
The purpose of this clinical trial is to evaluate the efficacy and safety of co-administrated BR1018B and BR1018C in patients with essential hypertension and primary hypercholesterolemia
- Trial name
- NCT06165250
- Testing
- BR1018A, BR1018A-1, BR1018B
- Where
- 2 sites in South Korea
- Volunteers
- 151 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd